



## **TERRASCEND TO HOST FOURTH QUARTER 2019 INVESTOR CONFERENCE CALL**

TORONTO, April 09, 2020 // - TerrAscend Corp. ("TerrAscend") (CSE:TER, OTCQX: TRSSF), a leading North American cannabis operator, today announced a scheduled conference call to discuss the results for its fourth quarter ended December 31, 2019 on Friday, April 24<sup>th</sup>, 2020 at 8:00 a.m. Eastern Time. The Company will report its financial results for the fourth quarter and full year 2019 in advance of the call.

### **CONFERENCE CALL DETAILS**

DATE: Friday, April 24<sup>th</sup>, 2020  
TIME: 8:00 a.m. Eastern Time  
WEBCAST: [Click to Access](#)  
DIAL-IN NUMBER: 1 (888) 664-6392  
CONFERENCE ID: 21459450  
REPLAY: (416) 764-8677 or (888) 390-0541  
Available until 12:00 midnight Eastern Time Friday, May 8<sup>th</sup>, 2020

***The Canadian Securities Exchange ("CSE") has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.***

### **About TerrAscend**

TerrAscend provides quality products, brands, and services to the global cannabinoid market. As the first North American Operator (NAO), with scale operations in both Canada and the US, TerrAscend participates in the medical and legal adult use market across Canada and in several US states where cannabis has been legalized for therapeutic or adult use. TerrAscend was the first cannabis company with sales in the US, Canada, and Europe. TerrAscend operates a number of synergistic businesses, including The Apothecarium, an award-winning cannabis dispensary with several retail locations in California; Arise Bioscience Inc., a manufacturer and distributor of hemp-derived products; Ilera Healthcare, Pennsylvania's premier medical marijuana cultivator, processor and dispenser; and Valhalla Confections, a manufacturer of premium cannabis-infused edibles. TerrAscend holds a cultivation permit in the State of New Jersey and is pending approval for a vertically integrated medical cannabis operation with the ability to operate up to 3 Alternative Treatment Centers. Additionally, TerrAscend holds a Medical Cannabis Processor License in the State of Utah. For more information, visit [www.terrascend.com](http://www.terrascend.com).

### **Caution Regarding Cannabis Operations in the United States**

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it

provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend's operations and financial performance.

*For more information regarding TerrAscend:*

Adam Kozak  
Chief Financial Officer  
IR@terrascend.com  
1-905-273-0213

Rob Kelly  
Investor Relations, Mattio Communications  
TerrAscend@mattio.com  
1-416-992-4539